![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dimethylhydrazine | decreases expression | ISO | Lmo3 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of LMO3 mRNA | CTD | PMID:22206623 | 17alpha-ethynylestradiol | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Ethinyl Estradiol results in decreased expression of LMO3 mRNA | CTD | PMID:18936297 | 17alpha-ethynylestradiol | affects expression | ISO | LMO3 (Homo sapiens) | 6480464 | Ethinyl Estradiol affects the expression of LMO3 mRNA | CTD | PMID:20170705 and PMID:26865667 | 17beta-estradiol | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Estradiol results in decreased expression of LMO3 mRNA | CTD | PMID:21185374 more ... | 2-methylcholine | affects expression | ISO | LMO3 (Homo sapiens) | 6480464 | beta-methylcholine affects the expression of LMO3 mRNA | CTD | PMID:21179406 | 3,3',5,5'-tetrabromobisphenol A | increases expression | ISO | LMO3 (Homo sapiens) | 6480464 | tetrabromobisphenol A results in increased expression of LMO3 mRNA | CTD | PMID:33476716 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | LMO3 (Homo sapiens) | 6480464 | [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LMO3 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of LMO3 mRNA | CTD | PMID:16997883 and PMID:28628672 | 4,4'-sulfonyldiphenol | decreases expression | ISO | Lmo3 (Mus musculus) | 6480464 | bis(4-hydroxyphenyl)sulfone results in decreased expression of LMO3 mRNA | CTD | PMID:30951980 | 8-Br-cAMP | multiple interactions | ISO | LMO3 (Homo sapiens) | 6480464 | [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LMO3 mRNA | CTD | PMID:16997883 | aflatoxin B1 | increases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Aflatoxin B1 results in increased expression of LMO3 mRNA | CTD | PMID:22100608 | all-trans-retinoic acid | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Tretinoin results in decreased expression of LMO3 mRNA | CTD | PMID:21934132 | arsenite(3-) | increases methylation | ISO | LMO3 (Homo sapiens) | 6480464 | arsenite results in increased methylation of LMO3 promoter | CTD | PMID:23974009 | belinostat | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | belinostat results in decreased expression of LMO3 mRNA | CTD | PMID:26272509 | belinostat | multiple interactions | ISO | LMO3 (Homo sapiens) | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA | CTD | PMID:27188386 | benzo[a]pyrene | affects methylation | ISO | LMO3 (Homo sapiens) | 6480464 | Benzo(a)pyrene affects the methylation of LMO3 5' UTR | CTD | PMID:27901495 | benzo[a]pyrene | decreases methylation | ISO | LMO3 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased methylation of LMO3 promoter | CTD | PMID:27901495 | bis(2-ethylhexyl) phthalate | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Diethylhexyl Phthalate results in decreased expression of LMO3 mRNA | CTD | PMID:31163220 | bisphenol A | affects expression | ISO | LMO3 (Homo sapiens) | 6480464 | bisphenol A affects the expression of LMO3 mRNA | CTD | PMID:20170705 | bisphenol A | decreases expression | ISO | Lmo3 (Mus musculus) | 6480464 | bisphenol A results in decreased expression of LMO3 mRNA | CTD | PMID:32156529 | bisphenol A | increases expression | ISO | Lmo3 (Mus musculus) | 6480464 | bisphenol A results in increased expression of LMO3 mRNA | CTD | PMID:30951980 | bisphenol A | decreases methylation | ISO | Lmo3 (Mus musculus) | 6480464 | bisphenol A results in decreased methylation of LMO3 promoter | CTD | PMID:27312807 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of LMO3 mRNA | CTD | PMID:25181051 | bisphenol F | decreases expression | ISO | Lmo3 (Mus musculus) | 6480464 | bisphenol F results in decreased expression of LMO3 mRNA | CTD | PMID:30951980 | C60 fullerene | decreases expression | EXP | | 6480464 | fullerene C60 results in decreased expression of LMO3 mRNA | CTD | PMID:19167457 | crocidolite asbestos | increases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Asbestos and Crocidolite results in increased expression of LMO3 mRNA | CTD | PMID:25351596 | cyclosporin A | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Cyclosporine results in decreased expression of LMO3 mRNA | CTD | PMID:33631201 | dexamethasone | multiple interactions | ISO | LMO3 (Homo sapiens) | 6480464 | [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LMO3 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of LMO3 mRNA | CTD | PMID:16997883 and PMID:28628672 | dexamethasone | increases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Dexamethasone results in increased expression of LMO3 mRNA | CTD | PMID:25047013 | Diallyl sulfide | multiple interactions | ISO | LMO3 (Homo sapiens) | 6480464 | allyl sulfide inhibits the reaction [tobacco tar analog results in decreased expression of LMO3 mRNA] | CTD | PMID:36758788 | dibutyl phthalate | decreases expression | EXP | | 6480464 | Dibutyl Phthalate results in decreased expression of LMO3 mRNA | CTD | PMID:21266533 | dorsomorphin | multiple interactions | ISO | LMO3 (Homo sapiens) | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | entinostat | multiple interactions | ISO | LMO3 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA | CTD | PMID:27188386 | entinostat | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | entinostat results in decreased expression of LMO3 mRNA | CTD | PMID:26272509 | ethanol | affects splicing | ISO | Lmo3 (Mus musculus) | 6480464 | Ethanol affects the splicing of LMO3 mRNA | CTD | PMID:30319688 | folic acid | decreases expression | ISO | Lmo3 (Mus musculus) | 6480464 | Folic Acid results in decreased expression of LMO3 mRNA | CTD | PMID:25629700 | genistein | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Genistein results in decreased expression of LMO3 mRNA | CTD | PMID:25136773 and PMID:26865667 | indometacin | multiple interactions | ISO | LMO3 (Homo sapiens) | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of LMO3 mRNA | CTD | PMID:28628672 | lead(0) | affects methylation | ISO | LMO3 (Homo sapiens) | 6480464 | Lead affects the methylation of LMO3 gene | CTD | PMID:31636367 | maneb | multiple interactions | ISO | Lmo3 (Mus musculus) | 6480464 | [Maneb co-treated with Paraquat] results in decreased expression of LMO3 mRNA | CTD | PMID:36117858 | mercury dibromide | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | mercuric bromide results in decreased expression of LMO3 mRNA | CTD | PMID:26272509 | mercury dibromide | multiple interactions | ISO | LMO3 (Homo sapiens) | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA | CTD | PMID:27188386 | methylmercury chloride | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | methylmercuric chloride results in decreased expression of LMO3 mRNA | CTD | PMID:23179753 more ... | N-methyl-4-phenylpyridinium | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | 1-Methyl-4-phenylpyridinium results in decreased expression of LMO3 mRNA | CTD | PMID:24810058 | nickel atom | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Nickel results in decreased expression of LMO3 mRNA | CTD | PMID:24768652 and PMID:25583101 | p-chloromercuribenzoic acid | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | p-Chloromercuribenzoic Acid results in decreased expression of LMO3 mRNA | CTD | PMID:26272509 | p-chloromercuribenzoic acid | multiple interactions | ISO | LMO3 (Homo sapiens) | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA | CTD | PMID:27188386 | panobinostat | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | panobinostat results in decreased expression of LMO3 mRNA | CTD | PMID:26272509 | panobinostat | multiple interactions | ISO | LMO3 (Homo sapiens) | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA | CTD | PMID:27188386 | paraquat | decreases expression | EXP | | 6480464 | Paraquat results in decreased expression of LMO3 mRNA | CTD | PMID:32680482 | paraquat | multiple interactions | ISO | Lmo3 (Mus musculus) | 6480464 | [Maneb co-treated with Paraquat] results in decreased expression of LMO3 mRNA | CTD | PMID:36117858 | phenylmercury acetate | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in decreased expression of LMO3 mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | LMO3 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA | CTD | PMID:27188386 | potassium dichromate | decreases expression | ISO | Lmo3 (Mus musculus) | 6480464 | Potassium Dichromate results in decreased expression of LMO3 mRNA | CTD | PMID:23608068 | rotenone | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Rotenone results in decreased expression of LMO3 mRNA | CTD | PMID:29955902 | SB 431542 | multiple interactions | ISO | LMO3 (Homo sapiens) | 6480464 | [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | serpentine asbestos | decreases methylation | ISO | LMO3 (Homo sapiens) | 6480464 | Asbestos and Serpentine results in decreased methylation of LMO3 5' UTR | CTD | PMID:29523930 | Soman | decreases expression | EXP | | 6480464 | Soman results in decreased expression of LMO3 mRNA | CTD | PMID:19281266 | sunitinib | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Sunitinib results in decreased expression of LMO3 mRNA | CTD | PMID:31533062 | temozolomide | increases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Temozolomide results in increased expression of LMO3 mRNA | CTD | PMID:31758290 | trichostatin A | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of LMO3 mRNA | CTD | PMID:24935251 and PMID:26272509 | trichostatin A | multiple interactions | ISO | LMO3 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA | CTD | PMID:27188386 | triclosan | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Triclosan results in decreased expression of LMO3 mRNA | CTD | PMID:30510588 | tunicamycin | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Tunicamycin results in decreased expression of LMO3 mRNA | CTD | PMID:22378314 | valproic acid | affects expression | ISO | LMO3 (Homo sapiens) | 6480464 | Valproic Acid affects the expression of LMO3 mRNA | CTD | PMID:25979313 | valproic acid | multiple interactions | ISO | LMO3 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of LMO3 mRNA | CTD | PMID:23179753 more ... | valproic acid | increases methylation | ISO | LMO3 (Homo sapiens) | 6480464 | Valproic Acid results in increased methylation of LMO3 gene | CTD | PMID:29154799 | vinclozolin | affects expression | EXP | | 6480464 | vinclozolin affects the expression of LMO3 mRNA | CTD | PMID:19015723 | vinclozolin | increases methylation | EXP | | 6480464 | vinclozolin results in increased methylation of LMO3 gene | CTD | PMID:31682807 | vitamin E | increases expression | ISO | LMO3 (Homo sapiens) | 6480464 | Vitamin E results in increased expression of LMO3 mRNA | CTD | PMID:19244175 | |